Immunoadsorption in Anti-GBM Glomerulonephritis.

计划入组 8 人 · 首次发布于 2016 年 5 月 9 日

A Study With Imlifidase in Anti-GBM Disease

计划入组 50 人 · 首次发布于 2023 年 1 月 11 日

A Clinical Trial With KJ103 in Anti-GBM Disease

计划入组 12 人 · 首次发布于 2024 年 9 月 23 日

Gbm-12401

Gbm-12407

GBM-108

Novel Anti-Infective Technologies, LLC

AiCuris Anti-Infective Cures AG

Germany

AGENCE REGIONALE DE SANTE DE LA REUNION

Reunion

Hansa Biopharma's Phase 3 Trial for Anti-GBM Disease Fails Primary Endpoint Despite Improved Dialysis-Free Outcomes

Hansa Biopharma's Imlifidase Shows Promise in Guillain-Barré Syndrome and Anti-GBM Disease

Imlifidase Shows Promise in Guillain-Barré Syndrome and Expands Gene Therapy Access